Quick Verdict
This article reviews the main highlights from the LENZ Therapeutics Q2 2026 Earnings report. LENZ reported a Q2 2026 EPS loss of $1.02, beating consensus by $0.19, while revenue of $5.486 million surpassed estimates by $3.109 million. Shares closed down 2.8% at $5.21 before rising 4.4% after hours, as VIZZ commercialization gained early traction and licensing revenue materially boosted quarterly results overall.
About LENZ Therapeutics
LENZ Therapeutics, Inc. (Nasdaq: LENZ) is a commercial-stage ophthalmology-focused biopharmaceutical company centered on VIZZ, its once-daily aceclidine 1.44% eye drop for presbyopia, the age-related loss of near vision. The company traces its origins to Presbyopia Therapies, LLC, formed in September 2013; it converted into a Delaware corporation in October 2020. Its principal office is in Solana Beach, California, within the San Diego area.lenz-tx+1
At the August 11 close, LENZ had a market capitalization of approximately $163.4 million, based on a $5.21 share price. The company is not profitable, so its reported P/E was -1.27, and it pays no dividend. LENZ employed 152 people according to the latest finance-profile data. The investment case is highly concentrated: commercial uptake of VIZZ in the U.S., patient refills, and monetization of international licensing partnerships are the principal revenue drivers.
Top Financial Highlights
- Total Q2 revenue was $5.486 million, compared with $5.000 million in Q2 2025.
- Net product sales were $1.736 million, generated from approximately 27,000 VIZZ packs sold and delivered.
- Product revenue increased 9% sequentially from Q1 2026; LENZ had no product sales in Q2 2025 because VIZZ had not yet launched.
- License revenue reached $3.750 million, including a $2.5 million Théa regulatory milestone and $1.25 million in Greater China sublicensing revenue.
- Net loss widened to $31.918 million, versus $14.912 million a year earlier.
- Basic and diluted EPS was a loss of $1.02, compared with a $0.53 loss in Q2 2025.
- Cost of sales totaled $0.280 million; calculated product gross margin was approximately 83.9% ($1.736m−$0.280m)/$1.736m(\$1.736m-\$0.280m)/\$1.736m($1.736m−$0.280m)/$1.736m. Management expects direct product gross margin to trend toward about 90% over time.
- SG&A expense increased to $39.378 million, chiefly reflecting salesforce, marketing, advertising, and launch infrastructure investment.
- Adjusted SG&A was approximately $34.9 million, down 14% from Q1 2026 after excluding non-cash stock compensation.
- R&D expense was zero, versus $9.061 million in Q2 2025, following VIZZ’s FDA approval in July 2025.
- Cash, cash equivalents, and marketable securities were $220.0 million at June 30, 2026.
- Operating cash flow was not disclosed in the earnings release.
- LENZ issued no quantitative Q3 2026 revenue, EPS, or cash-burn guidance.
- More than 13,000 unique eye-care professionals had prescribed VIZZ through Q2; approximately 75% had prescribed it more than once.
- More than 60% of patients in LENZ’s dominant ePharmacy channel had purchased multiple packs since launch, with early cohorts tracking toward five packs annually.
Financial Information
(Source: ir.lenz-tx.com)
Beat or Miss?
LENZ beat the tracked consensus estimates for both revenue and EPS. The revenue surprise was driven primarily by ex-U.S. licensing and milestone income, meaning the headline beat should not be interpreted solely as U.S. VIZZ product-sales outperformance.
| Metric | Reported | Difference/Analysis |
| Revenue | $5.486 million | Beat consensus of $2.377 million by $3.109 million. |
| EPS | −$1.02-\$1.02−$1.02 | Better than consensus loss of −$1.21-\$1.21−$1.21 by $0.19 per share. |
| Product sales | $1.736 million | No published consensus figure in the reviewed data; 9% sequential increase. |
| License revenue | $3.750 million | Key contributor to the total-revenue beat; includes Théa and Greater China-related milestone payments. |
| Q3 2026 guidance | Not provided | LENZ gave commercial commentary but no quantitative financial outlook. |
What Leadership Is Saying
CEO Eef Schimmelpennink emphasized patient persistence and a consumer-access strategy built around telehealth and direct-to-consumer advertising:
“Our focus is now on bringing more consumers into the category and making access as seamless as possible. Through telehealth, eligible consumers can be evaluated online by an independent licensed eye care professional and, if prescribed, receive VIZZ at home.”
CFO Dan Chevallard focused on the product’s expected margin structure, controlled commercial spending, and capital allocation:
“Our cost of sales on second quarter product revenue totaled $0.3 million, and we continue to anticipate VIZZ to trend to an approximately 90% direct product gross margin over time. Total SG&A expenses decreased to $39.4 million in the second quarter, or approximately $34.9 million adjusted to exclude non-cash stock-based compensation.”
Historical Performance
| Category | Q2 2026 | Q2 2025 | Change (%) |
| Revenue | $5.486 million | $5.000 million | 9.70% |
| Net income (loss) | −$31.918million-\$31.918 million−$31.918million | −$14.912million-\$14.912 million−$14.912million | Loss widened 114.0% |
| Total operating expenses | $39.658 million | $21.857 million | 81.40% |
| SG&A expense | $39.378 million | $12.796 million | 207.70% |
| R&D expense | $0 | $9.061 million | -100.0% |
The modest total-revenue increase masks a major change in mix: 2025 revenue was entirely license-related, while Q2 2026 included $1.736 million of newly commercialized VIZZ product revenue but lower license revenue. The much larger loss principally reflects commercial-launch spending rather than R&D, which fell to zero after approval.
How the Market Reacted?
LENZ shares closed August 11 at $5.21, down $0.15 or 2.80% during the regular session. Following the earnings release, the stock traded at $5.44 after hours, up $0.23 or 4.41% from the close, signaling an initially constructive reaction to the revenue and EPS beat.
Financial earnings data showed a near-flat one-day post-earnings move of approximately +0.01%, so the early response was positive but restrained.
Sources
